Фармаковигиланс

Pharmacovigilance is the process of detecting, assessing, and preventing drug-related adverse effects that emerge during post-marketing surveillance. It becomes critical once drugs are used by broader patient populations over extended periods, revealing unanticipated adverse drug reactions not identified during clinical trials. This monitoring protects public health by identifying safety signals early.

Data collection relies on spontaneous reporting systems where healthcare professionals or patients voluntarily report suspected adverse drug reactions. In some jurisdictions, reporting is a legal requirement. These reports form the foundation for detecting safety signals and identifying potential causal relationships between drugs and adverse events that were previously unknown.

A signal is a potential causal link between a drug and an adverse event that was not previously identified. Signals are detected by analyzing reported data from the spontaneous reporting system to find patterns suggesting a drug caused a specific adverse effect. This detection process is essential for identifying emerging safety concerns.

Causality assessment examines the temporal relationship between drug administration and the adverse reaction, the pharmacological plausibility of the reaction, and outcomes of dechallenge and rechallenge tests. These elements help determine whether the drug actually caused the adverse event. The assessment grades causality as definite, probable, possible, or unlikely.

Regulatory bodies disseminate safety findings through drug alerts, medical journals, and updates to drug labels with warnings or precautions. In severe cases, drugs may be withdrawn from the market entirely. These communication channels ensure healthcare professionals and patients receive critical information about identified adverse effects and risks.

Dechallenge involves stopping the suspected drug to observe whether the adverse reaction resolves, suggesting causality. Rechallenge involves reintroducing the drug to determine if the adverse reaction recurs, further confirming the causal relationship. Both tests strengthen the causality assessment by providing temporal and biological evidence of drug-related harm.

Clinical trials involve limited patient populations over short periods, so rare or long-term adverse effects may not emerge. Post-marketing surveillance exposes drugs to diverse patient populations with varying ages, comorbidities, and concurrent medications over extended periods. This broader real-world use reveals unanticipated adverse drug reactions that clinical trials could not detect.